Outpatient care concept and potential inpatient cost savings associated with the administration of dalbavancin - A real-world data and retrospective cost analysis

• Egile Nagusiak: Christoph T. Baltin (Egilea), Carolin Wulf (Egilea), Robert Rongisch (Egilea), Clara Lehmann (Egilea), Sebastian Wingen-Heimann (Egilea), Nicole Eisenmenger (Egilea), Jennifer Bonn (Egilea), Mario Fabri (Egilea), Esther von Stebut (Egilea), Oliver A. Cornely (Egilea), Florian Kron (Egilea)
• Formatua: Liburua
• Argitaratua: Elsevier, 2023-06-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Background: The treatment of acute bacterial skin and skin structure infections (ABSSSI) usually involves intravenous (i.v.) antibiotics requiring hospitalisation and increasing hospital costs. Since 2014, dalbavancin is approved for ABSSSIs treatment. However, evidence of its health economic impact...